NCT02983695View on ClinicalTrials.gov

Cannabinoid Therapy for Pediatric Epilepsy

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 2, 2017

Primary Completion Date

August 24, 2018

Study Completion Date

July 20, 2021

Conditions
Epilepsy
Interventions
DRUG

TIL-TC150

The active ingredients in TIL-TC150 are tetrahydrocannabinol (THC) and Cannabidiol (CBD), isolated from the Cannabis sativa L. strains produced by Tilray, and formulated into an oral liquid drug product.

Trial Locations (1)

M5G 1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

Tilray

INDUSTRY

lead

The Hospital for Sick Children

OTHER

NCT02983695 - Cannabinoid Therapy for Pediatric Epilepsy | Biotech Hunter | Biotech Hunter